Skip to main content

Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research

Agency: National Institutes of Health

Assistance Listings
  • 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Forecasted opportunityLast Updated: May 13, 2026

Important dates

  • Forecasted post date: April 1, 2026
  • Forecasted application due date: June 25, 2026
  • Forecasted award date: April 1, 2027
  • Forecasted project start date: May 1, 2027
  • Fiscal Year: 2027

Award details

  • Expected project funding: $5,200,000
  • Expected awards: 8

Award min.

Not specified

Award max.

Not specified

  • Funding opportunity number:RFA-DK-27-140
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Grant
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Health
  • Category Explanation:Not specified

History

  • Forecast posted date: February 4, 2026
  • Archive date: Not specified
  • Version: 1

View version history on Grants.gov

Summary

The main goal of this initiative is to establish a consortium with the overarching goal to advance the systematic identification, rigorous evaluation, validation, and assays harmonization of biomarkers that are critical to the prevention, diagnosis, and clinical management of Type 1 Diabetes (T1D). Despite significant advances in T1D research, there remains an urgent need for reliable and reproducible biomarkers that can capture the complexity of autoimmune processes, metabolic dysregulation, and individual patient variability. This initiative will leverage state-of-the-art methodologies in clinical chemistry, genomics, proteomics, metabolomics, immunophenotyping, and imaging, coupled with longitudinal patient cohorts and mining of Electronic Health Records (EHR). Within this consortium major efforts will be devoted to: 1) Harmonize established assays for biomarkers such as HbA1c and c-peptide, making sure that these assays are performed in a rigorous and reproducible manner in the clinical research community and in clinical practice. For this purpose, reference methods and materials will use a metrology approach and will be made available to the community; 2) Identify and validate other biomarkers that can be used for the prevention, diagnosis, and clinical management of T1D. It has been reported that the assays for several biomarkers routinely used in clinical research such as glucagon, amylin, chromogranin, insulin, pro-insulin and other pro-hormones are not reproducible across platforms or laboratories. For this purpose, this consortium will ensure that all assays for biomarkers routinely used in clinical research and for newly identified biomarkers are rigorously validated and assessed for reproducibility across several laboratories following a metrology approach. 

Eligibility

Business

  • For-profit organizations other than small businesses
  • Small businesses

Education

  • Public and state institutions of higher education
  • Private institutions of higher education
  • Independent school districts

Government

  • State governments
  • Special district governments
  • Public and Indian housing authorities
  • Federally recognized Native American tribal governments
  • County governments

Nonprofit

  • Other Native American tribal organizations
  • Nonprofits non-higher education with 501(c)(3)
  • Nonprofits non-higher education without 501(c)(3)

Miscellaneous

  • Other

Additional information on eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Documents

No documents are currently available.

Agency contact information

Email: NIDDK_DEM@nih.gov

NIDDK_DEM@nih.gov

Division of Diabetes, Endocrinology and Metabolic Diseases NIDDK_DEM@nih.gov

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov